How Much Does Oral Micronized Progesterone Cost in Maryland in 2026?

Maryland Retail Pricing: Brand vs. Generic vs. Compounded

The price you pay depends entirely on which version your prescriber writes for. Brand Prometrium, manufactured by AbbVie (the successor to Solvay Pharmaceuticals), carries a wholesale acquisition cost that translates to roughly $180 per month at Maryland pharmacies without insurance. Generic micronized progesterone capsules, available from manufacturers including Teva and Mylan, average $45 per month cash-pay across Maryland retail locations in 2026.

A third option exists. Licensed 503A compounding pharmacies in Maryland can prepare micronized progesterone capsules, troches, or suppositories at approximately $25 per month. Maryland permits 503A compounding under state pharmacy board oversight, provided the pharmacy holds a valid Maryland Board of Pharmacy license and compounds pursuant to a patient-specific prescription [1]. The FDA distinguishes 503A pharmacies (patient-specific) from 503B outsourcing facilities (batch production), and both pathways are legal in the state [2].

Price variation within Maryland is real. A 2024 AAFP analysis found that cash-pay prescription costs for the same generic drug can vary by 300% across pharmacies within a single ZIP code [3]. Calling ahead or using a pharmacy price-comparison tool before filling your prescription is worth the five minutes.

The gap between $180 (brand) and $25 (compounded) raises an obvious question: is the compounded version equivalent? The FDA has not evaluated compounded progesterone for bioequivalence, and the Endocrine Society's 2022 position statement cautions that compounded bioidentical hormones lack the standardized testing required of FDA-approved products [4]. Patients choosing the compounded route should confirm their pharmacy participates in voluntary third-party verification programs like PCAB accreditation.

What Maryland Medicaid Covers (and What It Requires)

Maryland Medicaid covers oral micronized progesterone for endometrial protection in patients receiving estrogen therapy. The catch: it requires prior authorization. Your prescriber must document that you are on concurrent estrogen, that you have an intact uterus, and that progesterone is medically necessary to reduce the risk of endometrial hyperplasia [5].

The PA process typically takes 24 to 72 hours. Once approved, the copay is $0 to $3 for most Maryland Medicaid recipients. The state's Medicaid Pharmacy Program maintains a preferred drug list (PDL) updated quarterly, and generic micronized progesterone has appeared on the PDL since 2019 [6].

Maryland expanded Medicaid under the Affordable Care Act, and the state covers approximately 1.5 million residents through Medicaid and the Maryland Children's Health Program. For HRT-eligible patients, this makes oral micronized progesterone one of the most accessible prescription options in the state. Denial rates for PA requests citing appropriate endometrial protection indications are low. The ACOG Practice Bulletin on hormone therapy provides the clinical framework most PA reviewers reference when evaluating requests [7].

If your initial PA is denied, Maryland law entitles you to a fair hearing through the Office of Administrative Hearings. But first, have your prescriber call the Medicaid pharmacy help desk directly. Many denials result from incomplete clinical documentation rather than formulary exclusion.

Commercial Insurance Coverage Across Maryland

Most commercial plans sold in Maryland through the Maryland Health Benefit Exchange (the state ACA marketplace) and employer-sponsored plans cover generic oral micronized progesterone on Tier 1 or Tier 2. Typical copays range from $10 to $35 per month depending on the plan.

CareFirst BlueCross BlueShield, the dominant insurer in the state, lists generic micronized progesterone on its preferred formulary without step therapy. Kaiser Permanente Mid-Atlantic similarly covers the generic without prior authorization for patients with documented estrogen use [8]. UnitedHealthcare plans in Maryland generally require the generic; brand Prometrium triggers a non-preferred tier copay of $50 to $75 or requires a formulary exception.

A few strategies reduce out-of-pocket costs further:

90-day fills. Most Maryland insurers offer lower per-unit pricing for 90-day supplies through mail-order or preferred retail pharmacies. A 90-day generic fill may cost $90 to $100, compared to $135 for three separate 30-day fills.

Manufacturer savings cards. AbbVie offers a Prometrium savings card that reduces brand copays to as low as $25 per month for commercially insured patients. The card does not apply to government insurance (Medicaid, Medicare Part D, Tricare). Eligibility can be verified at the manufacturer's website.

Pharmacy discount programs. GoodRx, RxSaver, and Cost Plus Drugs (Mark Cuban's venture) all list generic micronized progesterone. GoodRx coupons in Maryland ZIP codes show prices between $15 and $38 for a 30-day supply of 100 mg capsules as of May 2026.

Why Oral Micronized Progesterone and Not Synthetic Progestins?

The distinction matters clinically and financially. Oral micronized progesterone is bioidentical, meaning its molecular structure is identical to the progesterone produced by the human ovary. Synthetic progestins like medroxyprogesterone acetate (Provera) differ structurally and carry a different risk profile.

The landmark PEPI trial (N=875), published in JAMA in 1995, demonstrated that oral micronized progesterone provided effective endometrial protection while preserving the beneficial HDL cholesterol effects of estrogen therapy. Medroxyprogesterone acetate, by contrast, blunted estrogen's HDL benefit by approximately 50% [9]. This finding shifted prescribing patterns in the late 1990s and remains a foundational reference in HRT guidelines.

The Women's Health Initiative (WHI) further influenced the conversation. The estrogen-plus-progestin arm used medroxyprogesterone acetate, not micronized progesterone. The 2002 WHI results showed increased breast cancer risk with the synthetic progestin combination [10]. Observational data from the French E3N cohort (N=80,377) found that micronized progesterone combined with estrogen did not increase breast cancer risk over a mean follow-up of 8.1 years, while synthetic progestins did [11]. The E3N data, published in Breast Cancer Research and Treatment, is frequently cited by the North American Menopause Society in its position statements.

Dr. JoAnn Manson, principal investigator of the WHI and professor at Harvard Medical School, has noted: "The type of progestogen matters. Micronized progesterone appears to have a more favorable risk profile than synthetic progestins, particularly regarding breast and cardiovascular outcomes" [12].

Financially, generic micronized progesterone and generic medroxyprogesterone acetate are comparably priced. A 30-day supply of medroxyprogesterone 10 mg costs roughly $10 to $20 at Maryland pharmacies, making it cheaper. But the clinical advantages of micronized progesterone often justify the additional $25 to $30 per month for patients and providers focused on long-term safety.

Dosing, Forms, and How Maryland Patients Fill Prescriptions

Oral micronized progesterone comes in 100 mg and 200 mg capsules. The capsules contain progesterone suspended in peanut oil. This matters. Patients with peanut allergies should not take the standard formulation. Compounding pharmacies in Maryland can prepare peanut-free alternatives using olive oil or other carriers.

Standard dosing follows two patterns:

Continuous regimen. 100 mg nightly, taken every day alongside estrogen. This is the most common regimen for postmenopausal women on continuous combined HRT.

Cyclic regimen. 200 mg nightly for 12 to 14 days per calendar month. This approach produces a predictable withdrawal bleed and is often preferred by perimenopausal patients or those recently postmenopausal.

The FDA-approved labeling for Prometrium specifies 200 mg daily for 12 days sequentially per 28-day cycle when used for endometrial protection [2]. Some clinicians prescribe 100 mg continuously based on data suggesting equivalent endometrial protection at the lower dose for patients on standard-dose estrogen patches, though this use is off-label.

The capsule should be taken at bedtime. Progesterone has a sedative effect mediated by its metabolite allopregnanolone, a positive allosteric modulator of GABA-A receptors [13]. This is not a side effect to avoid. It is a benefit. Patients frequently report improved sleep onset and sleep quality. The 2017 Endocrine Society Clinical Practice Guideline for menopause management acknowledges this property and recommends bedtime dosing [14].

In Maryland, prescriptions for oral micronized progesterone can be filled at any licensed retail pharmacy, 503A compounding pharmacy, or through mail-order services. Telehealth prescribing is legal in the state, meaning Maryland residents can receive a prescription from a licensed provider via video visit and have it shipped or filled locally.

Telehealth Access in Maryland: How It Works

Maryland permits telehealth prescribing of oral micronized progesterone without geographic restrictions within the state. A provider licensed in Maryland can evaluate a patient via synchronous video, review labs, and transmit a prescription electronically to any Maryland pharmacy.

The Maryland Telehealth Prescribing Act, updated in 2023, removed the prior requirement for an initial in-person visit before prescribing controlled and non-controlled substances [15]. Progesterone is not a controlled substance, so telehealth prescribing faces no scheduling barriers.

Several telehealth platforms serve Maryland patients for HRT. HealthRX, Midi Health, Evernow, and Alloy Health all prescribe oral micronized progesterone to Maryland residents. Costs vary. Some platforms charge a monthly membership ($49 to $149 per month) that includes provider visits and may include the medication. Others charge per visit ($99 to $250) with the prescription filled separately.

The North American Menopause Society (NAMS) has stated: "Telehealth is an appropriate modality for initiating and managing menopausal hormone therapy in patients who have had appropriate baseline evaluation, including mammography and assessment of cardiovascular risk factors" [16].

For Maryland patients outside the Baltimore-Washington corridor, telehealth eliminates a real access barrier. Cecil, Garrett, Allegany, and Somerset counties have fewer than two menopause-trained providers per 100,000 residents according to NAMS-certified clinician data.

How to Get the Lowest Price in Maryland: A Decision Framework

The cheapest path depends on your insurance status.

If you have Maryland Medicaid: Ask your prescriber to submit prior authorization for generic micronized progesterone. Copay will be $0 to $3. Time from request to approval: 1 to 3 business days.

If you have commercial insurance: Check your formulary first. If the generic is Tier 1, your copay may be $10 to $15. Request a 90-day supply for additional savings. If you're paying more than $35 per month, apply a GoodRx or RxSaver coupon at a pharmacy that accepts discount cards.

If you are uninsured or underinsured: Three options, ranked by cost:

1. Compounded progesterone from a Maryland 503A pharmacy: approximately $25 per month.
2. Generic micronized progesterone with a discount card at Costco or independent pharmacies: $15 to $38 per month.
3. Cost Plus Drugs (online pharmacy model): approximately $12 to $20 per month for generic, shipped to Maryland.

If you have Medicare Part D: Coverage varies by plan. Most Part D formularies include generic micronized progesterone. The 2025 Inflation Reduction Act cap of $2,000 annual out-of-pocket on Part D spending applies, though progesterone's low cost means few patients hit this threshold from progesterone alone [17].

Safety Considerations for Maryland Patients

Oral micronized progesterone is generally well tolerated. The most commonly reported side effects include drowsiness (which resolves by taking the dose at bedtime), dizziness, bloating, and breast tenderness. The PEPI trial reported a dropout rate of 8% for the micronized progesterone arm compared to 12% for the medroxyprogesterone arm due to side effects [9].

Contraindications listed on the FDA label include known or suspected breast cancer, active deep vein thrombosis or pulmonary embolism, active arterial thromboembolic disease, known liver dysfunction or disease, known hypersensitivity to progesterone or any excipient (including peanuts), and undiagnosed abnormal genital bleeding [2].

The E3N cohort data offers reassurance specific to breast safety. Over 8.1 years of follow-up, women using estrogen combined with micronized progesterone showed a relative risk of breast cancer of 1.00 (95% CI: 0.83 to 1.22) compared to never-users of HRT [11]. This contrasts with the synthetic progestin combination, which carried a relative risk of 1.69 (95% CI: 1.50 to 1.91).

Dr. Avrum Bluming, oncologist and co-author of "Estrogen Matters," has stated: "The data consistently suggest that micronized progesterone does not share the breast cancer signal seen with synthetic progestins. Clinicians should distinguish between progestogen types when counseling patients about HRT risks" [18].

Maryland patients should have a baseline mammogram and cardiovascular risk assessment before starting any HRT regimen. The USPSTF recommends biennial mammography for women aged 40 to 74 [19]. Annual follow-up labs, including a lipid panel and metabolic panel, are standard of care during HRT.

Compounded Progesterone Legality in Maryland: What the Law Says

Compounded progesterone is legal in Maryland when prepared by a licensed 503A pharmacy pursuant to a valid patient-specific prescription. The Maryland Board of Pharmacy regulates compounding pharmacies under COMAR 10.34.19 and requires compliance with USP 795 standards for non-sterile compounding [20].

Patients should verify three things before using a Maryland compounding pharmacy for progesterone:

1. The pharmacy holds an active Maryland Board of Pharmacy license.
2. The pharmacy follows USP 795 (non-sterile) or USP 797 (sterile, if applicable) standards.
3. The pharmacy can provide a Certificate of Analysis for the active pharmaceutical ingredient.

The distinction between FDA-approved generic micronized progesterone and compounded versions is not trivial. The FDA-approved product has demonstrated bioequivalence through pharmacokinetic studies. Compounded versions have not. The FDA's 2023 advisory on compounded bioidentical hormones reiterates that compounding is appropriate when a patient cannot use an FDA-approved alternative due to allergy, dosing needs, or other medical reasons [2].

For Maryland patients with peanut allergies, compounding is the clearest medical justification. For patients choosing compounded progesterone solely based on cost, the decision involves weighing a $20 per month savings against the absence of standardized bioequivalence data.